Mel-Mont Medical has developed a new preventive comprehensive diagnostic system for cervical cancer called Mía by XytoTest.
The new system comes with a medical device that enables self-collection of cervical cells in any setting without assistance.
The collected sample is later analysed to identify human papillomavirus (HPV) using a molecular system of real-time polymerase chain reaction (PCR).
The same cells can also be used for a progressive protein analysis to identify the potential risk of high-grade lesions (CIN 2+) or cervical cancer in samples of high-risk HPV positive.
Mel-Mont Medical chief operating officer Frank Meléndez said: "The idea for Mía by XytoTest arose from the need to raise awareness on the importance of the culture of self-care and prevention to fight diseases with high morbidity and mortality rates that are paradoxically preventable, such as cervical cancer.”
The test is based on the discovery by German doctor Harald Zur Hausen that HPV causes cervical cancer.
Mel-Mont Medical chief executive officer Liliana Montes said: "We created Mía by XytoTest to reduce sociocultural barriers that prevent the participation of women in the organised screening programmes of cervical cancer, giving them the possibility of obtaining their sample from the comfort of their home or in the doctor's office without the need for professional assistance.”
The comprehensive system is expected to improve gynaecological intervention, prevent unnecessary deaths and provide better population coverage to prevent cervical cancer.
As compared to the Pap smear test with 30%-50% sensitivity, the new preventive diagnostic system is claimed to hold 96% sensitivity in the results.